Aprea Therapeutics: Buy Rating Reiterated as APR-1051 Clinical Momentum Builds; $1.20 Price Target Maintained
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Aprea Therapeutics with a $1.20 price target, citing clinical momentum for lead drug APR-1051. Key drivers include increased active sites and accelerated enrollment in the Phase 1 ACESOT-1051 study, alongside strategic expansion into combination therapies for HPV-positive head and neck cancer and KRAS/TP53-mutant colorectal cancer. These developments validate the drug's tolerability profile and support a positive outlook.
Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Aprea Therapeutics, retaining the price target of $1.20.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Joseph Pantginis has given his Buy rating due to a combination of factors tied to the progress of Aprea’s lead WEE1 inhibitor program, APR-1051. He views the significant increase in active clinical sites for the Phase 1 ACESOT-1051 study and the guided acceleration in patient enrollment as a meaningful shift that should enable more robust and timely clinical data generation.
Pantginis also highlights the strategic expansion into combination settings in HPV-positive head and neck cancer and KRAS/TP53-mutant colorectal cancer as an important validation of APR-1051’s potential differentiation in tolerability. With biomarker-driven cohorts advancing in parallel and a clear timeline toward dose optimization by 2027, he believes the program’s evolving profile supports maintaining a positive stance on the stock, reflected in his unchanged $1.20 price target.